EMA Publishes Brexit Plan
The agency has published a continuity plan for its move from the United Kingdom.
On October 16, 2017, the European Medicines Agency (EMA) published a Brexit Preparedness Business Continuity Plan detailing how the agency will continue its operations while it prepares for relocation to a new host city because of the United Kingdom’s departure from the European Union. The plan, which was endorsed by the Management Board in June, was developed to deal with the workload implications and uncertainties related to Brexit.
The plan describes the methodology the agency has used to categorize and prioritize activities and the reallocation of resources, if needed. Tasks and activities have been classified into three categories based on priority. Activities in these categories are described as well as details regarding how and when implementation of changes will occur. The agency plans on continuously reviewing and adapting the plan as necessary.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
